Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ETON
#2436
Eton Pharmaceuticals, Inc. - Common Stock
38.5
0
USD
+0.03%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+2.64%
Monthly Change
+18.64%
6 month change
+158.22%
Year Change
+175.59%
Previous Close
37.5
1
Open
38.5
0
Low
38.5
0
High
38.5
0
Volume
45
Markets
US Stock Market
Healthcare
Drug Manufacturers—Specialty & Generic
ETON
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q1, 25
Q2, 25
Q3, 25
Q4, 25
Q1, 26
TTM
Cash from operating activities
2.09 M
7.96 M
12.03 M
-11.55 M
7.41 M
15.84 M
Cash from investing activities
0
0
-284 K
-49 K
-15.07 M
-15.41 M
Cash from financing activities
394 K
0
0
421 K
1.39 M
1.81 M
Free cash flow
2.09 M
7.96 M
12.03 M
-11.55 M
7.41 M
15.84 M
News
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists
GE Aerospace Hits Record High, Leads 19 Onto IBD 50, Big Cap 20, Other Best Stock Lists
AI Play And Memory-Chip Maker Micron Among 17 Newcomers To Today's Best Growth Stock Lists
Applied Materials Surges To Record High, Joins Dell, MDA Space, 17 Others On Best Stock Lists
Chip Equipment Maker KLA Hits Record High, Leads 16 Stars Onto Best Stock Lists
AI Cool Play Vertiv Joins 2 Best Stock Lists, Leads Group Of 14 New To IBD 50, Big Cap 20, More
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS)
Stock Market Leaders Respect The 21-Day Line. You Should Too.
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?